Published in Pharma Law Weekly, June 20th, 2006
Study 1: Recombinant leptospiral immunoglobulin-like protein A protects against Leptospira interrogans serovar Pomona infection.
"We previously reported the cloning and characterization of leptospiral immunoglobulin-like proteins LigA and LigB of Leptospira interrogans. LigA and LigB are conserved at the amino-terminal region but are variable at the carboxyl-terminal region. Here, we evaluate the potential of recombinant LigA (rLigA) as a vaccine candidate against infection by L. interrogans serovar Pomona in a hamster model. rLigA was truncated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.